Grace Therapeutics, Inc. Research and Development Expense
Grace Therapeutics, Inc. (GRCE) reported Research and Development Expense of $697.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Grace Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $697.00K, a 27.02% decline year-over-year.
- Grace Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $420.00K, a 74.30% decline year-over-year.
- Grace Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $462.00K, a 78.94% decline year-over-year.
- Grace Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $568.00K, a 80.91% decline year-over-year.
- Grace Therapeutics, Inc. research and development expense for fiscal 2026 was $2.40M, a 74.71% decline from fiscal 2025.
- Grace Therapeutics, Inc. research and development expense for fiscal 2025 was $9.51M, a 103.10% increase from fiscal 2024.
- Grace Therapeutics, Inc. research and development expense for fiscal 2024 was $4.68M, a 53.04% decline from fiscal 2023.
- Grace Therapeutics, Inc. research and development expense for fiscal 2023 was $9.97M, a 79.38% increase from fiscal 2022.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $697.00K 10-Q · filed 2026-08-13 | $1.12M derived: sum of 2 quarters · filed 2026-08-13 | $1.58M derived: sum of 3 quarters · filed 2026-08-13 | $2.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $882.00K derived: sum of 2 quarters · filed 2026-06-18 | $1.45M derived: sum of 3 quarters · filed 2026-06-18 | $2.40M 10-K · filed 2026-06-18 |
| 2025-12-31 | $462.00K 10-Q · filed 2026-02-12 | $1.03M derived: sum of 2 quarters · filed 2026-02-12 | $1.99M 10-Q · filed 2026-02-12 | $3.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $568.00K 10-Q · filed 2025-11-13 | $1.52M 10-Q · filed 2025-11-13 | $3.16M derived: sum of 3 quarters · filed 2026-08-13 | $5.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $955.00K 10-Q · filed 2026-08-13 | $2.59M derived: sum of 2 quarters · filed 2026-08-13 | $4.78M derived: sum of 3 quarters · filed 2026-08-13 | $7.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $3.83M derived: sum of 2 quarters · filed 2026-06-18 | $6.80M derived: sum of 3 quarters · filed 2026-06-18 | $9.51M 10-K · filed 2026-06-18 |
| 2024-12-31 | $2.19M 10-Q · filed 2026-02-12 | $5.17M derived: sum of 2 quarters · filed 2026-02-12 | $7.88M 10-Q · filed 2026-02-12 | $9.56M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $2.98M 10-Q · filed 2025-11-13 | $5.68M 10-Q · filed 2025-11-13 | $7.37M derived: sum of 3 quarters · filed 2025-11-13 | $8.81M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.71M 10-Q · filed 2025-08-12 | $4.39M derived: sum of 2 quarters · filed 2025-08-12 | $5.84M derived: sum of 3 quarters · filed 2025-08-12 | $6.30M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $3.13M derived: sum of 2 quarters · filed 2025-06-23 | $3.59M derived: sum of 3 quarters · filed 2025-06-23 | $4.68M 10-K · filed 2025-06-23 |
| 2023-12-31 | $1.44M 10-Q · filed 2025-02-13 | $1.90M derived: sum of 2 quarters · filed 2025-02-13 | $3.00M 10-Q · filed 2025-02-13 | $4.64M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $460.00K 10-Q · filed 2024-11-13 | $1.55M 10-Q · filed 2024-11-13 | $3.19M derived: sum of 3 quarters · filed 2024-11-13 | $5.64M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.09M 10-Q · filed 2024-08-09 | $2.73M derived: sum of 2 quarters · filed 2024-08-09 | $5.18M derived: sum of 3 quarters · filed 2024-08-09 | $8.48M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $4.09M derived: sum of 2 quarters · filed 2024-06-21 | $7.38M derived: sum of 3 quarters · filed 2024-06-21 | $9.97M 10-K · filed 2024-06-21 |
| 2022-12-31 | $2.45M 10-Q · filed 2024-02-12 | $5.74M derived: sum of 2 quarters · filed 2024-02-12 | $8.33M 10-Q · filed 2024-02-12 | $10.66M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | $3.29M 10-Q · filed 2023-11-13 | $5.88M 10-Q · filed 2023-11-13 | $8.21M derived: sum of 3 quarters · filed 2023-11-13 | $10.39M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.59M 10-Q · filed 2023-08-11 | $4.92M derived: sum of 2 quarters · filed 2023-08-11 | $7.09M derived: sum of 3 quarters · filed 2023-08-11 | $7.68M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | $4.50M derived: sum of 2 quarters · filed 2023-06-23 | $5.09M derived: sum of 3 quarters · filed 2023-06-23 | $5.56M 10-K · filed 2023-06-23 |
| 2021-12-31 | $2.18M 10-Q · filed 2023-02-14 | $2.76M derived: sum of 2 quarters · filed 2023-02-14 | $3.23M 10-Q · filed 2023-02-14 | $3.69M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-09-30 | $585.00K 10-Q · filed 2022-11-14 | $1.05M 10-Q · filed 2022-11-14 | $1.51M derived: sum of 3 quarters · filed 2022-11-14 | $2.19M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $469.00K 10-Q · filed 2022-08-11 | $922.00K derived: sum of 2 quarters · filed 2022-08-11 | $1.60M derived: sum of 3 quarters · filed 2022-08-11 | $2.89M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $1.13M derived: sum of 2 quarters · filed 2022-06-21 | $2.42M derived: sum of 3 quarters · filed 2022-06-21 | $4.17M 10-K · filed 2022-06-21 |
| 2020-12-31 | $678.00K 10-Q · filed 2022-02-14 | $1.96M derived: sum of 2 quarters · filed 2022-02-14 | $3.72M 10-Q · filed 2022-02-14 | $5.64M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $1.29M 10-Q · filed 2021-11-10 | $3.04M 10-Q · filed 2021-11-10 | $4.96M derived: sum of 3 quarters · filed 2021-11-10 | $8.87M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.76M 10-Q · filed 2021-08-12 | $3.67M derived: sum of 2 quarters · filed 2021-08-12 | $7.59M derived: sum of 3 quarters · filed 2021-08-12 | $11.54M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-22 | $5.83M derived: sum of 2 quarters · filed 2021-06-22 | $9.78M derived: sum of 3 quarters · filed 2021-06-22 | $15.97M 10-K · filed 2021-06-22 |
| 2019-12-31 | $3.91M 10-Q · filed 2021-02-09 | $7.87M derived: sum of 2 quarters · filed 2021-02-09 | $14.06M 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $3.95M 10-Q · filed 2020-11-16 | $10.14M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $6.19M 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | $29.37M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |